Journal article 742 views
CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma
Bernard Escudier,
Padmanee Sharma,
David F. McDermott,
Saby George,
Hans J. Hammers,
Sandhya Srinivas,
Scott S. Tykodi,
Jeffrey A. Sosman,
Giuseppe Procopio,
Elizabeth R. Plimack,
Daniel Castellano,
Howard Gurney,
Frede Donskov,
Katriina Peltola,
John Wagstaff,
Thomas C. Gauler,
Takeshi Ueda,
Huanyu Zhao,
Ian M. Waxman,
Robert J. Motzer
European Urology
Swansea University Author: John Wagstaff
Full text not available from this repository: check for access using links below.
DOI (Published version): 10.1016/j.eururo.2017.02.010
Abstract
CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma
| Published in: | European Urology |
|---|---|
| ISSN: | 03022838 |
| Published: |
2017
|
| Online Access: |
Check full text
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa34579 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| College: |
Faculty of Medicine, Health and Life Sciences |
|---|